Holen Sie sich die Stockscreener-App
10.81
2.95%
0.31
Handel nachbörslich:
9.06
-1.75
-16.19%
Biohaven Ltd Aktie (BHVN) Neueste Nachrichten
Biohaven's depression drug fails mid-stage trial, shares fall - marketscreener.com
Biohaven Stock Slumps After Hours As Failed Depression Study Adds To A Brutal 2025 — Retail Eyes Epilepsy And Obesity Catalysts - Asianet Newsable
Biohaven Shares Dive: Time to Reflect? - StocksToTrade
Biohaven (NYSE:BHVN) Stock Price Down 13%What's Next? - MarketBeat
Biohaven’s depression drug misses primary endpoint in Phase 2 study By Investing.com - Investing.com Australia
Biohaven stock falls after depression drug misses primary endpoint By Investing.com - Investing.com Australia
Biohaven falls as depression candidate fails in phase 2 - Seeking Alpha
Biohaven stock falls after depression drug misses primary endpoint - Investing.com
Depression drug trial falls short as Biohaven turns to obesity and epilepsy - Stock Titan
Wall Street Analysts Predict an 88.57% Upside in Biohaven Ltd. (BHVN): Here's What You Should Know - Nasdaq
Stock Watch: What Biohaven Can Teach Us About Optimism And Reality - Citeline News & Insights
Aug Weekly: Will Biohaven Ltd stock benefit from upcoming earnings reports - moha.gov.vn
Aug Reactions: What market sentiment indicators show for Biohaven Ltd. Common Shares stockMarket Growth Report & Reliable Price Breakout Signals - moha.gov.vn
Biohaven (BHVN) Is Down 5.9% After Strong Early BHV-1510 Combo DataHas The Bull Case Changed? - simplywall.st
How Biohaven Ltd. stock performs in high volatility markets2025 Price Action Summary & Verified Swing Trading Watchlists - Улправда
Why Biohaven Ltd. Common Shares stock is a strong analyst pickJuly 2025 Review & Free Technical Confirmation Trade Alerts - Улправда
Biohaven (BHVN): Valuation Check After Encouraging BHV-1510 Immuno-Oncology Data at ESMO Congress - Yahoo Finance Singapore
Biohaven (BHVN) Is Down 5.9% After New BHV-1510 Combo DataWhat's Changed - Yahoo Finance
Biohaven Ltd. (BHVN) Upgraded to Buy: Here's What You Should Know - sharewise.com
Can Biohaven Ltd. stock maintain operating marginsMarket Movement Recap & Community Consensus Picks - Улправда
First Week of February 2026 Options Trading For Biohaven (BHVN) - Nasdaq
Will Biohaven Ltd. stock continue dividend increasesJuly 2025 Retail & Step-by-Step Trade Execution Guides - DonanımHaber
(BHVN) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Is Biohaven Ltd. stock overvalued by current metricsQuarterly Profit Summary & Weekly Consistent Profit Watchlists - Улправда
Biohaven (BHVN) price target decreased by 23.10% to 19.95 - MSN
Biohaven (BHVN): Evaluating Valuation After New BHV-1510 Oncology Data at ESMO Immuno-Oncology Congress - simplywall.st
Bellevue Group AG Raises Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
105,803,655 Common shares of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain options of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain warrants of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Certain restricted share units of Biohaven Ltd. are subject to a Lock-Up Agreement Ending on 13-DEC-2025. - marketscreener.com
Biohaven Ltd. $BHVN Position Trimmed by Redmile Group LLC - MarketBeat
Armistice Capital LLC Raises Stock Holdings in Biohaven Ltd. $BHVN - MarketBeat
Biohaven Ltd. (NYSE:BHVN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Biohaven call volume above normal and directionally bullish - MSN
Biohaven jumps on early-stage data for antibody drug conjugate combo - Seeking Alpha
Why Biohaven (BHVN) Is Up 16.2% After New Trop2 ADC Combo Data At ESMO IO 2025 – And What's Next - simplywall.st
Biohaven stock jumps after promising cancer drug results By Investing.com - Investing.com Nigeria
Biohaven stock jumps after promising cancer drug results - Investing.com
Biohaven presents data for BHV-1510 at ESMO - TipRanks
Biohaven reports promising results for cancer drug BHV-1510 - Investing.com
Biohaven reports promising results for cancer drug BHV-1510 By Investing.com - Investing.com South Africa
Biohaven shares cancer drug trial results at European oncology meeting - StreetInsider
Biohaven Presents Clinical Safety and Efficacy Data for BHV-1510, a Next-Generation Trop2 Antibody Drug Conjugate in Combination with Cemiplimab at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress - PR Newswire
Biohaven (NYSE:BHVN) Stock Price Down 5%What's Next? - MarketBeat
Norges Bank Makes New $12.74 Million Investment in Biohaven Ltd. $BHVN - MarketBeat
Biohaven (NYSE:BHVN) Trading Up 8.8%Still a Buy? - MarketBeat
FY2025 EPS Estimates for Biohaven Increased by HC Wainwright - MarketBeat
Responsive Playbooks and the BHVN Inflection - news.stocktradersdaily.com
Biohaven Ltd. $BHVN Position Lowered by Panagora Asset Management Inc. - MarketBeat
Biohaven Ltd. (BHVN) Collaborates with Bexorg, Inc to Target Central Nervous System Disorders - MSN
How Much Upside is Left in Biohaven Ltd. (BHVN)? Wall Street Analysts Think 127.52% - Eastern Progress
Why Biohaven Ltd. stock could rally in 2025Jobs Report & Weekly Consistent Profit Watchlists - Newser
HC Wainwright Comments on Biohaven FY2029 Earnings - MarketBeat
Will Biohaven Ltd. Common Shares stock beat international competition2025 Institutional Moves & Weekly Setup with High ROI Potential - Newser
Will Biohaven Ltd. stock beat EPS estimatesJuly 2025 Sector Moves & Real-Time Chart Pattern Alerts - Newser
Does Biohaven Ltd. stock trade at a discount to peersWeekly Trend Summary & Stock Portfolio Risk Management - Newser
0.36%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):